Secondary Immunodeficiencies in the spotlight at IPIC 2025: Kedrion champions innovation and patient care

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

KEDRION-IPIC-2025

More Like This

PR Newswire associated0

Kedrion Biopharma closes 2024 with a growth of +10% and unveils its new identity

PR Newswire associated0

European Medicines Agency (EMA) grants Orphan Drug Designation to Kedrion's plasma-derived treatment for Congenital Aceruloplasminemia, a rare genetic disorder of iron metabolism

Sobi share new clinical data across multiple hematologic diseases at EHA 2025

Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023

PR Newswire associated0

Mallinckrodt Announces 2024 Extracorporeal Immunomodulation Award

Business Wire logo

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)

In-depth analysis showing robust Diamyd® treatment effects across clinical trials to be shared at the 2024 IDS Diabetes Congress

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm